Buprenorphine half-life
Buprenorphine is another long-tail opioid-treatment entry where persistence and clinical meaning need to stay separate.
Effects, impairment, and testing
None of these can be calculated from half-life alone.
Receptor activity, formulation, and treatment setting make clinical effects a different timeline from plasma decline.
Half-life versus durationSedation and respiratory risk cannot be reduced to the representative half-life or a percentage remaining.
Safety boundaryTesting may measure buprenorphine, norbuprenorphine, or both; this profile does not estimate any specimen window.
Why testing is differentEvery curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
What a careful reader should notice first
The curve can help explain why long half-lives matter, but treatment context and receptor pharmacology are outside a simple first-order display.
Source angle
Check whether sources refer to product labeling, route, formulation, or broader pharmacology before comparing values.
Do not use it for
Do not use this page for dosing, induction, withdrawal, pain control, or treatment planning.
Best next step
Compare with methadone and naloxone, then read steady-state guidance.
Buprenorphine: evidence and interpretation notes
Why the curve has a long tail
The 37-hour input sits within the 24-to-42-hour terminal half-life range reported in the linked tablet labeling. It is a representative point for drawing the curve, not a claim that every person or every buprenorphine product follows a 37-hour clock. Route and formulation matter, and terminal elimination is only one part of the drug’s clinical behavior.
At this setting, the normalized model reaches 50% after 37 hours, 25% after 74 hours, and about 3% after 185 hours. That slow decline makes buprenorphine a useful example of accumulation, but the percentages are not measured blood levels and do not describe receptor occupancy, withdrawal, analgesia, or treatment response.
What the sources contribute
The DailyMed record supplies product-specific labeling and the terminal range used to bound this page’s input. The pharmacokinetic study examines a buprenorphine/naloxone combination tablet, so it is useful for formulation context rather than proof that all products behave identically. PubChem is included as a compound identity record; it is not the basis for the 37-hour number.
| Evidence source | What it contributes | Important limit |
|---|---|---|
| DailyMed tablet labeling | Product-specific 24-to-42-hour terminal range | Other routes and formulations require separate evidence |
| Combination-tablet pharmacokinetics review | A roughly 32-hour estimate, sublingual absorption, and large between-person variation | It discusses a fixed combination product rather than every buprenorphine formulation |
| PubChem identity record | Compound identity | It does not establish the selected value |
The combination-tablet paper also shows why the two active ingredients should not be drawn as one line: sublingual naloxone levels are much lower and decline more rapidly than buprenorphine. The HalfLifeDB curve follows buprenorphine only.
Read the tail, not a dosing clock
Use the chart to see why a long terminal half-life creates a gradual tail and why repeated administration cannot be understood from a single-dose snapshot. Questions about induction, dosing, withdrawal, pain treatment, or switching medications require supervised clinical guidance and the labeling for the actual product involved.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 37 h as a representative input for Buprenorphine. In the simplified model, about 63.8% remains after 24 hours and about 3% remains after five half-lives, or roughly 7.7 days.
This is a long-tail curve. The page is most useful for understanding persistence and accumulation concepts, not for making decisions from one percentage. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
opioid treatment medication context
Opioid treatment medication pages need careful distinction between pharmacokinetic persistence, clinical treatment context, accumulation, and supervised dosing decisions.
- The curve is not a treatment, induction, tapering, or withdrawal guide.
- Long half-lives can make accumulation context especially important.
- Clinical decisions require supervised care, not a public calculator.
ComparisonTimeline checkpoints and nearby profiles
Buprenorphine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 24 h | 63.8% | Meaningful modeled decline, not near-zero |
| 3.0 days | 26.0% | Long-tail portion of the model |
| 5.0 days | 10.6% | Long-tail portion of the model |
| 7.0 days | 4.30% | Low modeled remainder, not a clearance guarantee |
| 14 days | 0.18% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Buprenorphine within the opioid treatment medication group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Methadone (24 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 37 h |
|---|---|
| Reported range | 24 h to 42 h |
| Curve type | Normalized, first-order decline |
Selection note: Representative terminal half-life for buprenorphine; labeling and reviews often report a broad range because formulation and study design matter.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: BUPRENORPHINE TABLET [UNIT DOSE SOLUTIONS, INC.].Official sublingual-tablet labeling used for the 24-to-42-hour terminal range and formulation context.
- Identity record PubChem Compound Summary: Buprenorphine.Compound identity record; background only, not numerical support.
- Research abstract PubMed: Pharmacokinetics of the combination tablet of buprenorphine and naloxone.Combination-tablet pharmacokinetics review describing a roughly 32-hour buprenorphine half-life, rapid sublingual absorption, and large between-person variability.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the opioid-treatment group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.